These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 18449951)

  • 1. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
    Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
    Pearson EC; Woosley RL
    Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced torsades de pointes in patients aged 80 years or more.
    Paran Y; Mashav N; Henis O; Swartzon M; Arbel Y; Justo D
    Anadolu Kardiyol Derg; 2008 Aug; 8(4):260-5. PubMed ID: 18676301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL; Lau YS; Teo WS
    Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
    Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W
    Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
    Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
    J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors.
    Justo D; Prokhorov V; Heller K; Zeltser D
    Acta Psychiatr Scand; 2005 Mar; 111(3):171-6. PubMed ID: 15701100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proarrhythmic potential of antimicrobial agents.
    Simkó J; Csilek A; Karászi J; Lorincz I
    Infection; 2008 Jun; 36(3):194-206. PubMed ID: 18454341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
    Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
    Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Droperidol, QT prolongation, and sudden death: what is the evidence?
    Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
    Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sotalol unmasks susceptibility to drug-induced long QT syndrome and torsades de pointes.
    Letsas KP; Efremidis M; Sideris A
    Int J Cardiol; 2008 Mar; 124(3):366-7; author reply 368-9. PubMed ID: 17400314
    [No Abstract]   [Full Text] [Related]  

  • 12. Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports.
    Justo D; Zeltser D
    Mycoses; 2006 Nov; 49(6):463-70. PubMed ID: 17022762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France.
    Perrin-Terrin A; Pathak A; Lapeyre-Mestre M
    Fundam Clin Pharmacol; 2011 Aug; 25(4):503-10. PubMed ID: 20825488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future.
    Layton D; Key C; Shakir SA
    Pharmacoepidemiol Drug Saf; 2003; 12(1):31-40. PubMed ID: 12616845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Citalopram induced torsade de pointes, a rare life threatening side effect.
    Kanjanauthai S; Kanluen T; Chareonthaitawee P
    Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes.
    Lin YL; Kung MF
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):235-9. PubMed ID: 19145580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of high-risk use of QT-prolonging medications.
    Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake.
    Yalta K; Turgut O; Yilmaz A; Yilmaz MB; Kendirlioglu O; Karadas F
    Int J Cardiol; 2007 Apr; 116(3):e95-7. PubMed ID: 17126428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.
    Zeltser D; Justo D; Halkin A; Prokhorov V; Heller K; Viskin S
    Medicine (Baltimore); 2003 Jul; 82(4):282-90. PubMed ID: 12861106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.